Interviews
With
Experts
Nicholas Johnston | Founder
2nd June 2025: Alis Biosciences is a London-based fund tackling the $30 billion trapped in struggling, publicly listed biotech companies. By acquiring and delisting these firms, Alis returns unused cash to shareholders while preserving valuable science through targeted structures. The goal is to offer a faster, more efficient alternative to traditional exits and recycle capital into high-potential innovation. Alis is currently engaging with boards, investors, and teams to scale this strategy. It also presents a compelling blueprint for de-risking public market exposure in biotech—a model that forward-thinking investors will want to watch closely.
Dr. Ryan Jackson | Phd
23rd May 2025: In this conversation, we sit down with Dr. Ryan Jackson, a leading structural biologist and faculty member at Utah State University, to explore the enduring relevance of X-ray crystallography in an era dominated by cryo-EM and AI-powered protein prediction tools like AlphaFold. Dr. Jackson shares his expert insights on when and why crystallography is still the gold standard for resolving novel protein structures, how it compares to newer technologies, and why young scientists should continue to value and learn this foundational technique.